Gynecologic Cancers Research Program

妇科癌症计划-摘要 斯蒂芬森癌症中心(SCC)妇科癌症(GC)计划的目标是提高 为所有患有妇科恶性肿瘤的妇女提供标准的护理并改善临床结果 重点解决与俄克拉何马州SCC集水区相关的问题。计划成员 通过进行跨学科、基于团队的研究来实现这一目标 分子机制进入早期和晚期随机试验。GC计划的具体目标 是：(1)发现和询问致癌的核心分子机制；(2)研究 癌症治疗反应和抵抗的潜在机制；以及(3)设计和进行早期和 晚期随机临床试验，推进新发现并改善患者预后 集水区和国家。 GC计划的亮点包括：1)高度互动的基本发现和临床成员专注于 妇科癌症；2)将这些项目成员组织成专注的翻译团队的具体目标， 导致多重PI赠款和方案内出版物的出类率；3)妇科 肿瘤学临床计划，通过提供多学科护理和获得 俄克拉何马州一半的新GC病例的临床试验(58%的登记率)；4)一个大型的注明生物素 支持GC发现研究的银行；5)积极开发以GC为重点的研究人员发起的试验 和GC患者对早期新治疗试验的高收益；以及6)设计方面的国家领先 以及进行改变实践的NCTN和行业赞助的随机GC试验。 GC计划有18名成员，代表7个系、4个学院和2个机构，其中 说明了计划成员的跨学科专业知识。该计划的翻译重点是 反映在医学博士(9)和博士(9)成员的平衡中。截至2016年12月31日，计划成员 每年获得3,865,290美元的NCI和其他同行评审的癌症相关支持(直接费用)。NCI资助 (3,181,558美元)占同行审查资金的82.3%，突显了该项目对癌症的关注。总计 每年GC计划的资金为8,700,601美元(直接成本)。五年报告期(2012-2016)，GC 计划成员发表了262篇同行评议文章，其中34.4%包括计划内，11.8% 包括方案间，73.3%包括机构间协作者。2016年，方案间 发表的论文占21.1%，突出了与临床前研究中心正在进行的合作数量的增加 转化型癌症研究(PTCR)和癌症预防和控制(CPC)计划。

GYNECOLOGIC CANCERS PROGRAM – ABSTRACT The goal of the Gynecologic Cancers (GC) program at the Stephenson Cancer Center (SCC) is to raise the standard of care and improve clinical outcomes for all women with gynecologic malignancies, with an emphasis on addressing problems relevant to Oklahoma, the SCC catchment area. Program members accomplish this goal by conducting transdisciplinary, team-based research that advances discovery of molecular mechanisms into early- and late-phase randomized trials. The Specific Aims for the GC program are: (1) to discover and interrogate molecular mechanisms central to carcinogenesis; (2) to investigate mechanisms underlying cancer therapy response and resistance; and (3) to design and conduct early- and late-phase randomized clinical trials that advance novel discoveries and improve patient outcomes in the catchment area and nation. Highlights of the GC program include: 1) highly interactive basic discovery and clinical members focused on gynecologic cancers; 2) Specific Aims that organize these program members into focused translational teams, leading to multi-PI grants and an exceptional rate of intra-programmatic publications; 3) a gynecologic oncology clinical program that impacts the catchment area by providing multidisciplinary care and access to clinical trials (58% enrollment rate) for half the new GC cases in Oklahoma; 4) a large annotated biospecimen bank that supports GC discovery research; 5) active development of GC-focused investigator-initiated trials and high accrual of GC patients to early-phase novel treatment trials; and 6) national leadership in the design and conduct of practice-changing NCTN- and Industry-sponsored randomized GC trials. The GC program has 18 members, representing seven departments, four colleges and two institutions, which illustrates the transdisciplinary expertise among program members. The translational focus of the program is reflected in the balance of MD (9) and PhD (9) members. As of December 31, 2016, program members were awarded $3,865,290 in annual NCI and other peer-reviewed cancer-related support (direct cost). NCI funding ($3,181,558) accounts for 82.3% of the peer-reviewed funding, highlighting the program's cancer focus. Total annual GC program funding is $8,700,601 (direct cost). For the five-year reporting period (2012-2016), GC program members published 262 peer-reviewed articles, of which 34.4% included intra-programmatic, 11.8% included inter-programmatic, and 73.3% included inter-institutional collaborators. For 2016, inter-programmatic publications were 21.1%, highlighting the increasing number of collaborations underway with the Preclinical Translational Cancer Research (PTCR) and Cancer Prevention and Control (CPC) programs.